---
title: 'Management of Patients with Breast Biopsy under Anti-Coagulation or Anti-Platelet
  Therapy: Results of a Survey of German Experts'
date: '2024-05-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38765898/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240520180926&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Breast biopsies for patients on ASA or prophylactic heparin
  are deemed safe and part of standard clinical practice. However, despite available
  feasibility studies, conducting breast biopsies on ACT medications such as DOACs
  or phenprocoumon appears feasible only for a minority of ...'
disable_comments: true
---
CONCLUSION: Breast biopsies for patients on ASA or prophylactic heparin are deemed safe and part of standard clinical practice. However, despite available feasibility studies, conducting breast biopsies on ACT medications such as DOACs or phenprocoumon appears feasible only for a minority of ...